U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07547813) titled 'A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa' on April 17.
Brief Summary: The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Hidradenitis Suppurativa
Intervention:
DRUG: LAD328
LAD328 administered intravenously.
OTHER: Placebo
Placebo administered intravenously.
Recruitment Status: NOT_YET_RECRUITING
Sp...